Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine Research"
DOI: 10.1080/07435800.2020.1713802
Abstract: ABSTRACT Background and aim: Sodium-glucose cotransporter (SGLT) 2 is responsible for most of the glucose reabsorption in the kidneys and has been proposed as a novel therapeutic target for the treatment of type 2 diabetes.… read more here.
Keywords: ipragliflozin; metformin; type diabetic; type ... See more keywords
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model
Sign Up to like & getrecommendations! Published in 2019 at "Physiological Reports"
DOI: 10.14814/phy2.14286
Abstract: Nonalcoholic steatohepatitis (NASH) has become the most common cause of chronic liver disease worldwide in recent years. The pathogenesis of NASH is closely linked to metabolic diseases such as insulin resistance, obesity, dyslipidemia, and type… read more here.
Keywords: nonalcoholic steatohepatitis; pioglitazone; type diabetes; insulin resistance ... See more keywords